AMGN vs BMY
By Alex · Tickerpine
Amgen Inc. vs Bristol-Myers Squibb Company, side by side — the numbers that matter, in plain English. No “winner” hype; you decide.
| Metric | AMGN | BMY |
|---|---|---|
| Price | $358.33 | $57.52 |
| Market cap | $193.39B | $117.46B |
| P/E ratio | 24.9 | 16.1 |
| ROE | 101.32% | 38.73% |
| Profit margin | 20.96% | 15.01% |
| Revenue growth | 5.80% | 2.60% |
| Dividend yield | 2.81% | 4.38% |
| Beta | 0.42 | 0.24 |
Green = the more favorable figure for that metric (lower P/E, higher ROE, margin, growth and yield). Not a recommendation.
AMGN vs BMY in plain English
- AMGN is the bigger company — about 1.6× the market cap of BMY.
- BMY is cheaper on earnings (P/E 16.1 vs 24.9).
- AMGN earns a higher return on equity (101% vs 39%).
- AMGN is growing revenue faster (6% vs 3%).
- BMY has the higher dividend yield (4.38% vs 2.81%).
How would $1,000 have done in each?
AMGN return calculator
See what $1,000 in Amgen Inc. would be worth today.
BMY return calculator
See what $1,000 in Bristol-Myers Squibb Company would be worth today.
Figures from public market data, may be delayed. Comparison is informational only — not investment advice.